Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1173936

	registered interest
	date	28/01/2020
	answering body	Department for International Development
	answering dept id	20
	answering dept short name	International Development
	answering dept sort name	International Development
	hansard heading	UK-Africa Investment Summit
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for International Development, whether representatives of (a) Shell International, (b) BP and (c) other oil and gas companies were invited to the UK-Africa Investment Summit.
	tabling member constituency	Coventry South
	tabling member printed	Zarah Sultana
	uin	9153
	answer	answer is ministerial correction date of answer 03/02/2020 answer text <p>More than 1,700 people attended the UK-Africa Investment Summit on 20 January 2020. This included Leaders and Ministers from African Governments, CEOs and senior representatives from African and British businesses, institutional investors, international organisations, financial institutions and civil society. Businesses from a wide range of sectors were invited, including the oil and gas sector.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 03/02/2020 16:01:39 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4786 label Biography information for Zarah Sultana

1698924

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS Greater Manchester: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when she last met with Greater Manchester NHS Board to discuss the statutory commissioning of NICE approved medicines.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20611
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20612 20613 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1698925

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS Greater Manchester: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what discussions NHS England have had with Greater Manchester NHS on their statutory responsibilities to commission NICE approved medicines.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20612
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20611 20613 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1698926

	registered interest
	date	26/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Treatments: Technology
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what guidance her Department issues NHS trusts on establishing commissioning structures for Health Technology Assessments; and whether trusts have discretion to adopt different processes.
	tabling member constituency	Makerfield
	tabling member printed	Yvonne Fovargue
	uin	20613
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>Ministers have not met with Greater Manchester NHS Board about the statutory commissioning of National Institute for Health and Care Excellence (NICE) recommended medicines. Similarly I am informed that NHS England is not aware of any such discussions.</p><p>The National Health Service in England is legally required to make funding available for treatments recommended in NICE technology appraisal and highly specialised technologies guidance, normally within three months of the publication of final guidance. This requirement is reflected in the NHS Constitution as a right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate.</p><p>The NHS Standard Contract is mandated by NHS England for use by commissioners for all contracts for healthcare services other than primary care. The 2024/25 standard contract states that, where any service involves or may involve the prescribing of medicines, the provider must ensure that its formulary reflects all relevant positive NICE technology appraisals. NICE’s guideline on developing and updating local formularies states that when a NICE technology appraisal recommends a medicine, it should be adopted into the local formulary automatically if clinically appropriate and relevant to the services provided by the organisation, and that this process should take place within three months.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20611 20612 question first answered 15/04/2024 08:04:14 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4034 label Biography information for Yvonne Fovargue

1682426

	registered interest
	date	16/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS Learning Support Fund: Pharmacy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of allowing pharmacy students to access the NHS Learning Support Fund.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	9790
	answer	answer is ministerial correction date of answer 22/01/2024 answer text <p>The Government keeps the funding arrangements for all healthcare students under close review. At all times the Government must strike a balance between the level of support students receive and the need to make best use of public funds to deliver value for money. There are no immediate plans to make changes to the scheme design.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 22/01/2024 10:42:24 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3924 label Biography information for Yasmin Qureshi

1683320

	registered interest
	date	18/01/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Cancer: Waiting Lists
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to reduce waiting times for treatments for (a) breast, (b) ovarian and (c) prostate cancer.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	10442
	answer	answer is ministerial correction date of answer 24/01/2024 answer text <p>Reducing waiting times for treatments of all types of cancer is a priority for the Government, as is increasing early cancer diagnosis as this is a key contributor to reducing cancer health inequalities. We are expanding capacity through our community diagnostic centres (CDCs) supported by £2.3 billion of capital funding with 150 CDCs currently operational and having delivered over six million additional tests, checks and scans including vital cancer checks since January 2021.</p><p>The planned Major Conditions Strategy will look at the early diagnosis and treatment of cancer and will consider a wide range of interventions and enablers to improve outcomes and experience for a range of cancer patients, including those less survivable cancers.</p><p>NHS England has commissioned six cancer clinical audits which will provide timely evidence for cancer service providers of where patterns of care in England may vary, increase the consistency of access to treatments and help stimulate improvements in cancer treatments and outcomes for patients, including ovarian cancer, pancreatic cancer, non-Hodgkin lymphoma, kidney cancer and primary and metastatic breast cancer. The Royal College of Surgeons began work on this audit in October 2022, and the first outcomes expected in September 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 24/01/2024 11:44:53 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3924 label Biography information for Yasmin Qureshi

1692747

	registered interest
	date	29/02/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Medical Equipment: Waste Disposal
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential merits of collecting data centrally about levels of (a) reuse and (b) discard of NHS equipment.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	16318
	answer	answer is ministerial correction date of answer 06/03/2024 answer text <p>The Department published the inaugural Medical Technology Strategy in February 2023, which included a focus on improving resource efficiency. The Department is working with industry, the health and care sector, and academic partners to develop medical technology systems that support reuse, remanufacture, and material recovery, by default. The Department is exploring options for reuse, remanufacture, and material recovery in medical devices, through its Design for Life programme. This includes developing regulatory, commercial, and infrastructure and policy environments that support these aims. As part of the programme, the Department recognises we will need to define future data requirements, and align digital infrastructure to improve the gathering of core data. <br> <br></p><p><br> NHS England has developed a waste planning tool for all National Health Service providers, consistent with the Clinical Waste Strategy, which includes improved waste segregation, minimisation, and increased reuse programmes. This will lead to reductions in the road miles the waste travels, increases in the use of re-usable sharps bins, and furthers plans made towards the achievement of Net Zero Carbon from waste management. <br> <br> NHS England has an ambition to expand existing walking aid refurbishment schemes. Arrangements for the return and reuse of walking aids are managed locally, and a number of NHS trusts already have local return and reuse schemes, with over 200 return sites now featured on the Recycle Now website. Further information is available at the following link:</p><p><a href="https://www.recyclenow.com/recycle-an-item/walking-aids" target="_blank">https://www.recyclenow.com/recycle-an-item/walking-aids</a></p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 06/03/2024 17:42:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3924 label Biography information for Yasmin Qureshi

1698355

	registered interest
	date	25/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Integrated Care Systems: Allergies and Nutrition
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she has made an assessment of the potential merits of each Integrated care systems having a (a) specialist allergy nurse and (b) dietitian.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	20254
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The majority of services for people living with allergies are commissioned locally through integrated care boards (ICBs), which are best placed to commission services according to local need. Specialised allergy services are provided for patients with severe and complex allergic conditions, or those who have common allergic conditions for which conventional management has failed and for whom specified specialist treatments are required. In 2023/24, these services are jointly commissioned by NHS England Specialised Commissioning and the ICBs, in line with the published Specialist Allergy Service Specification.</p><p>There is an established Clinical Reference Group (CRG), which is responsible for providing national clinical advice and leadership for specialised immunology and allergy services. The CRG uses its expertise to advise NHS England on the best ways to provide specialised services. This includes developing national standards in the form of service specifications and policies. The CRG commenced a review of the current service specification in May 2023, which is expected to be complete by summer 2024. The outcome of the service specification review will be an updated specification which references up-to-date guidance and takes into account the latest evidence base, to clearly define the standards of care for commissioned specialised services.</p><p>To help promote awareness of allergies, the National Institute for Health and Care Excellence (NICE) has published guidance on a range of allergy conditions, including food allergy in under 19-year-olds, anaphylaxis, and drug allergy. The NICE promotes its guidance via its website, newsletters, and other media.</p><p>To support clinicians in the implementation of clear care pathways, the NICE website has guidance to support diagnosis and treatment of a range of allergy conditions, including how to identify allergies and when to refer to specialist care, and how to ensure allergies are recorded in their medical records.  The NICE website also provides primary care practitioners with access to clinical knowledge summaries outlining the current evidence base and practical guidance on a range of skin conditions.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20255 question first answered 15/04/2024 08:15:46 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3924 label Biography information for Yasmin Qureshi

1698356

	registered interest
	date	25/03/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Allergies: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps her Department is taking to improve allergy awareness in health care settings.
	tabling member constituency	Bolton South East
	tabling member printed	Yasmin Qureshi
	uin	20255
	answer	answer is ministerial correction date of answer 15/04/2024 answer text <p>The majority of services for people living with allergies are commissioned locally through integrated care boards (ICBs), which are best placed to commission services according to local need. Specialised allergy services are provided for patients with severe and complex allergic conditions, or those who have common allergic conditions for which conventional management has failed and for whom specified specialist treatments are required. In 2023/24, these services are jointly commissioned by NHS England Specialised Commissioning and the ICBs, in line with the published Specialist Allergy Service Specification.</p><p>There is an established Clinical Reference Group (CRG), which is responsible for providing national clinical advice and leadership for specialised immunology and allergy services. The CRG uses its expertise to advise NHS England on the best ways to provide specialised services. This includes developing national standards in the form of service specifications and policies. The CRG commenced a review of the current service specification in May 2023, which is expected to be complete by summer 2024. The outcome of the service specification review will be an updated specification which references up-to-date guidance and takes into account the latest evidence base, to clearly define the standards of care for commissioned specialised services.</p><p>To help promote awareness of allergies, the National Institute for Health and Care Excellence (NICE) has published guidance on a range of allergy conditions, including food allergy in under 19-year-olds, anaphylaxis, and drug allergy. The NICE promotes its guidance via its website, newsletters, and other media.</p><p>To support clinicians in the implementation of clear care pathways, the NICE website has guidance to support diagnosis and treatment of a range of allergy conditions, including how to identify allergies and when to refer to specialist care, and how to ensure allergies are recorded in their medical records.  The NICE website also provides primary care practitioners with access to clinical knowledge summaries outlining the current evidence base and practical guidance on a range of skin conditions.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20254 question first answered 15/04/2024 08:15:46 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3924 label Biography information for Yasmin Qureshi

1667913

	registered interest
	date	07/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Screening
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of diagnostic tests have been carried out by the NHS (a) in total, (b) six weeks and (c) ten weeks after a referral in the last 12 months.
	tabling member constituency	Ilford North
	tabling member printed	Wes Streeting
	uin	327
	answer	answer is ministerial correction date of answer 29/11/2023 answer text <p>Diagnostic test activity across the 15 test types recorded by NHS England was 25.6 million in the 12 months to September 2023. The data requested for diagnostic tests at six weeks and ten weeks after a referral is not collected by NHS England in the format requests.</p><p>The NHS’ Delivery Plan for tackling the COVID-19 backlog of elective care aims for 95% of patients needing a diagnostic test to receive it within six weeks by March 2025. NHS England aims to increase diagnostic activity to 120% of pre-pandemic levels by March 2025 to support this.</p><p>In the 2021 spending review £2.3 billion was awarded to transform diagnostic services over the next three years. Most of this will help increase the number of Community Diagnostic Centres up to 160 by March 2025, expanding and protecting elective planned diagnostic services. The remainder of the funding will increase capacity for imaging, endoscopy as well as lung and mammography screening, and improve digital diagnostics.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 29/11/2023 13:49:58 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4504 label Biography information for Wes Streeting